CME General Session· Saturday, May 4, 2019 · Phoenix, AZ · 10:20 – 11:00am

The Story Continues: Heart Failure and Type 2 Diabetes

Chaired by: Matthew R. Weir, MD

Due to the close association of HF and T2D, it is important that clinicians are aware of the increased morbidity and mortality in this high-risk population. As such, comprehensive strategies to address both HF and T2D are necessary to improve outcomes for these patients. Recent studies have shown that certain antihyperglycemic agents can prevent HF in patients with and without T2D, and several ongoing studies are evaluating the utility of these agents in treating existing HF. This evidence has led to significant guideline changes, and clinicians that treat the complex T2D patient have additional tools in their disposal to improve outcomes. As such, clinicians should be aware of the existing and emerging data, how to interpret these data and more importantly, how to adequately use these agents in clinical practice. This activity will overview the association of HF and T2D, as well as appropriate HF and antihyperglycemic therapy in this setting according to the latest evidence base.

Learning Objectives
After completing this activity, the participant should be better able to:

• Review the association and the pathophysiology between HF and T2D, and the impact of concomitant HF and T2D on patient outcomes
• Develop individualized treatment regimens for high-risk patients with HF and T2D based on the latest data about the efficacy and safety of HF and T2D pharmacotherapies and appropriate guideline recommendations

This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine. Supported by an educational grant from Boehringer Ingelheim and Lilly USA, LLC.

CME Lunch Symposium · Saturday, May 4, 2019 · Phoenix, AZ · 12:15 – 1:30pm

Advances in Iron Repletion Therapy: Addressing the Burden of Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life

Chaired by: Clyde W. Yancy, MD, MSc, MACP

Iron deficiency (ID) affects up to one-third of the world's population and is particularly common in elderly individuals and those with certain chronic diseases such as chronic kidney disease, and congestive heart failure. Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with heart failure (HF), ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients.

In this symposium, experts will provide participants with data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. Recent updates to established HF treatment guidelines that emphasize ID recognition and treatment will also be addressed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.

Learning Objectives
After completing this activity, the participant should be better able to:

• Define the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life
• Identify the symptoms of ID using appropriate markers in HF patients in order to diagnose ID
• Summarize the evidence from the latest clinical trials of iron repletion in HF patients with ID, as well as the updated ACC/AHA/HFSA guidelines for the management of iron deficiency in patients with HF
• Develop individualized treatment regimens to manage ID in HF patients, including the administration of intravenous iron, based on the latest evidence and current guideline recommendations

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from American Regent.